Xencor (XNCR) Short-term Investments (2015 - 2026)
Xencor's (XNCR) quarterly Short-term Investments came in at $370.2 million in Q1 2026, up 657.53% year-on-year from $48.9 million in Q1 2025, and down 2.87% on a QoQ basis from $381.2 million in Q4 2025.
Xencor (XNCR) Short-term Investments (2015 - 2026) Analysis & Trends
Xencor (XNCR) has 12 years of Short-term Investments data on file, last reported at $370.2 million in Q1 2026.
- On a quarterly basis, Short-term Investments rose 657.53% year-over-year to $370.2 million in Q1 2026; TTM through Mar 2026 was $370.2 million, a 657.53% increase from a year earlier, with the FY2025 full-year figure at $381.2 million, down 6.8% from the prior year.
- Short-term Investments for Q1 2026 stood at $370.2 million, down from $381.2 million in the prior quarter.
- Over the last five years, Short-term Investments for XNCR reached as high as $497.7 million in Q4 2023 and fell as low as $26.9 million in Q2 2022.
- Historically, Short-term Investments has averaged $193.3 million across 5 years, with a median of $48.9 million in 2025.
- Across the five-year window, Short-term Investments slumped 90.94% in 2022 and soared 1182.71% in 2023, its largest moves.
- Year by year, Short-term Investments stood at $42.4 million in 2022, then jumped by 1073.02% to $497.7 million in 2023, then slipped by 17.83% to $409.0 million in 2024, then dropped by 6.8% to $381.2 million in 2025, then fell by 2.87% to $370.2 million in 2026.
- Per Business Quant data, the three most recent Short-term Investments figures were $370.2 million in Q1 2026, $381.2 million in Q4 2025, and $84.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 370.21 Mn |
| Dec 31, 2025 | 381.16 Mn |
| Sep 30, 2025 | 84.26 Mn |
| Jun 30, 2025 | 358.98 Mn |
| Mar 31, 2025 | 48.87 Mn |
| Dec 31, 2024 | 408.97 Mn |
| Sep 30, 2024 | 435.04 Mn |
| Jun 30, 2024 | 28.27 Mn |
| Mar 31, 2024 | 44.54 Mn |
| Dec 31, 2023 | 497.73 Mn |
| Sep 30, 2023 | 412.83 Mn |
| Jun 30, 2023 | 40.00 Mn |
| Mar 31, 2023 | 39.71 Mn |
| Dec 31, 2022 | 42.43 Mn |
| Sep 30, 2022 | 32.18 Mn |
| Jun 30, 2022 | 26.89 Mn |
| Mar 31, 2022 | 33.43 Mn |
| Dec 31, 2021 | 36.86 Mn |
| Sep 30, 2021 | 47.58 Mn |
| Jun 30, 2021 | 45.23 Mn |